“The present situation has exposed some structural weaknesses inside the EU’s medicines offer chain along with a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She proposed that provide chain issues be dealt with within an EU pharmaceutical system expecte